Valuation: GENFIT

Market Cap 434M 486M 401M 363M 679M 46.11B 691M 4.82B 1.91B 24.16B 1.82B 1.78B 76.17B P/E 2026 *
-417x
P/E 2027 * -886x
Enterprise Value 406M 454M 375M 340M 635M 43.12B 646M 4.51B 1.79B 22.59B 1.7B 1.67B 71.22B EV / Sales 2026 *
5.1x
EV / Sales 2027 * 3.05x
Free-Float
86.79%
Yield 2026 *
-
Yield 2027 * -
1 day-2.47%
1 week+3.21%
Current month-12.60%
1 month-4.20%
3 months-35.49%
6 months+5.99%
Current year+64.67%
1 week 8.11
Extreme 8.11
9.55
1 month 7.72
Extreme 7.72
10.26
Current year 5.05
Extreme 5.05
15.48
1 year 3.4
Extreme 3.4
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
5/3/26 Exercice

Chief Operating Officer

11,250 0.0225%
5/3/26 Exercice

Chief Operating Officer

7,083 0.0142%
5/3/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
-2.47%+3.21%+132.44%+186.14% 486M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.00%+2.49%+56.51%+145.41% 38.36B
Weighted average by Cap. +0.39%+2.73%+46.13%+142.89%

Financials

2026 *2027 *
Net sales 79.46M 88.98M 73.4M 66.52M 124M 8.45B 127M 883M 350M 4.43B 334M 327M 13.95B 128M 143M 118M 107M 200M 13.58B 203M 1.42B 562M 7.12B 537M 525M 22.43B
Net income -1.09M -1.23M -1.01M -916K -1.71M -116M -1.74M -12.16M -4.81M -60.93M -4.6M -4.5M -192M 4.87M 5.45M 4.5M 4.07M 7.62M 517M 7.75M 54.1M 21.42M 271M 20.45M 20.02M 855M
Net Debt -28.18M -31.56M -26.04M -23.6M -44.14M -3B -44.87M -313M -124M -1.57B -118M -116M -4.95B -43.67M -48.9M -40.34M -36.56M -68.39M -4.64B -69.52M -485M -192M -2.43B -184M -180M -7.67B
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
180
Date Price Change Volume
23/10/26 EUR 8.670 -2.47% 167,768
22/10/26 EUR 8.890 -4.10% 406,182
21/10/26 EUR 9.270 +3.00% 304,234
20/10/26 EUR 9.000 +8.30% 288,689
19/10/26 EUR 8.310 -1.07% 193,353
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.670EUR
Average target price
17.48EUR
Spread / Average Target
+101.61%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT
  1. Stock Market
  2. Stocks
  3. GNFT Stock